Nano-X Imaging Ltd. current report, Q3 FY2020

Full document

Nano-X Imaging Ltd. Form 6-K Summary

Business Context and Reporting Period

Nano-X Imaging Ltd. filed this Form 6-K on September 10, 2020, covering September 2020. The filing reports progress in the U.S. Food and Drug Administration’s 510(k) Third Party Review Program for the Nanox.ARC imaging system.

Regulatory and Operational Update

  • On September 3, 2020, the Company submitted its official response to an accredited FDA Review Organization’s request for additional information regarding the single-source Nanox.ARC.
  • The response included additional data and information addressing deficiencies identified by the reviewer, including results from certain performance tests.
  • The response was submitted within the required timeframe.
  • The original 510(k) application was submitted in January 2020, and the additional information request was received in March 2020.
  • The application relies on a predicate filing for an equivalence claim to an existing FDA-approved X-ray imaging system. The Company stated that it made no new claims regarding the Nanox.ARC’s operation, image quality, or functionality versus the predicate device.

Financial Metrics and Material Changes

This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It also does not report a financial comparison with a prior period.

The Company stated that its original application timeline was delayed by COVID-19-related impacts on external laboratories used for product testing.

Outlook, Risks, and Contingencies

  • The Company plans to continue optimizing the Nanox.ARC and developing additional features.
  • It plans to submit an additional 510(k) application for the multiple-source Nanox.ARC during the fourth quarter of 2020.
  • Regulatory clearance remains contingent on the FDA Third Party Review Program’s evaluation of the submitted response and application materials.
  • Further delays may result from regulatory review, product testing, external laboratory capacity, or the continuing effects of COVID-19.

Key Facts for Investors to Verify

  1. Whether the FDA or its accredited Review Organization accepted the response and granted 510(k) clearance for the single-source Nanox.ARC.
  2. Whether the planned fourth-quarter 2020 application for the multiple-source Nanox.ARC was submitted and its subsequent regulatory status.
  3. The nature and resolution of the deficiencies identified in the additional information request.
  4. The effect of testing, regulatory, and COVID-19-related delays on commercialization timing and future financial results.